Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | RARG | P13631 | 13/20 | 0.47 |
| ▸ | RARB | P10826 | 8/20 | 0.47 |
| ▸ | RARA | P10276 | 6/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847030 | 0.91 | RARG (0.51) | EGFRRARGRARBRARAPDK2 | |
| SCHEMBL5845588 | 0.90 | RARB (0.48) | RARGRARBRARAPDK2RXRA | |
| SCHEMBL2918656 | 0.90 | EGFR (0.67) | EGFRRARGRARBRARARXRA | |
| SCHEMBL5847014 | 0.88 | RARG (0.47) | EGFRRARGRARBRARAPDK2 | |
| SCHEMBL5846165 | 0.86 | RARG (0.60) | RARGRARBRARAPDK2RXRA | |
| SCHEMBL5847708 | 0.86 | PDK2 (0.49) | EGFRRARGRARBRARAPDK2 | |
| SCHEMBL2944374 | 0.85 | EGFR (0.52) | EGFRRARGRARBRARARXRA | |
| SCHEMBL5847730 | 0.84 | RARG (0.46) | EGFRRARGRARBRARAPDK2 | |
| SCHEMBL5846406 | 0.83 | RARG (0.55) | RARGRARBRARAPDK2RXRA | |
| SCHEMBL5846284 | 0.83 | RARG (0.61) | RARGRARBRARARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148245-B2 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20040030141-A1 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT | 2004-02-12 | — | — | US | disclosed |
| US-6649612-B1 | Combating skin ageing and keratinization | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-11-18 | — | — | US | disclosed |
| US-6316009-B1 | FOR THERAPY OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH A KERATINIZATION DISORDER, AND FOR COMBATING AGEING OF THE SKIN | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030141-A1 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | AHR, TYR, CYP1A1 | EGFR 227/4885RARG 39/4885RARB 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.